TLR7 antagonist-1
TLR7 antagonist-1 (Compound 44#) is an orally active, selective TLR7 antagonist with an IC50 value of 0.3 nM against TLR7. TLR7 antagonist-1 selectively binds to TLR7, inhibits its activation, and downregulates the c-Rel signaling pathway. TLR7 antagonist-1 downregulates the mRNA levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α. TLR7 antagonist-1 alleviates Imiquimod (HY-B0180)-induced psoriasis-like skin lesions. TLR7 antagonist-1 is applicable to research related to psoriasis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 3104353-70-7
- 分子式: C21H25ClF3N5O
- 分子量:455.90
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
IL-1β |
IL-6 |
TLR7 0.3 nM (IC50) |
TLR7 antagonist-1 potently and selectively inhibits TLR7 in HEK-Blue-HTLR7 cells with an IC50 of 0.3 nM, while exhibiting much weaker activity against TLR8 and TLR9[1].
TLR7 antagonist-1 (0.005-5 μM; 12 h) inhibits TLR7-mediated inflammatory cytokines in a concentration-dependent manner in RAW264.7 and HEK-Blue-HTLR7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 cells, HEK-Blue-HTLR7 cells
-
Concentration:0.005-5 μM (RAW264.7 cells); 0.005-5 μM (HEK-Blue-HTLR7 cells)
-
Incubation Time:12 h
-
Result:Concentration-dependently downregulated R848-induced mRNA levels of IL-1β, IL-6, TNF-α in RAW264.7 cells.
Concentration-dependently reduced IFN-α mRNA levels in HEK-Blue-HTLR7 cells, with 0.5 μM showing better efficacy than 5 μM Enpatoran (HY-134581).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C (female, 6 weeks old, 15-16 g, imiquimod-induced psoriasis-like dermatitis)[1]
-
Dosage:15 mg/kg; 45 mg/kg
-
Administration:p.o.
-
Result:Reduced PASI scores significantly compared to the model group, with only slight skin thickening appearing from day 18.
Reduced epidermis/stratum corneum thickening, Munro microabscesses, and subdermal lymphocyte infiltration compared to the model group, with dermis and cuticle thickness near control levels.
Reversed spleen enlargement, with spleen weights near control levels.
Reduced mRNA levels of NF-κB p65 and c-Rel in skin tissue in a dose-dependent manner, with high-dose group c-Rel levels comparable to control group.
Reduced serum and skin tissue levels of inflammatory cytokines IL-17A and IL-1β in a dose-dependent manner.
Normalized elevated white blood cell counts, lymphocyte counts, and lymphocyte percentages in the model group to control levels.
Reduced model group increases in ALT, AST, BUN, and Scr in a dose-dependent manner, with high-dose group showing the most significant liver and renal function protection.
Showed no significant differences in body weight, liver/kidney weight, or histopathological damage to liver, kidney, or spleen across groups.
化学情報
-
CAS 番号 3104353-70-7
-
分子量 455.90
-
分子式 C21H25ClF3N5O
-
SMILES
CC1=CN(C2=N1)C=C(C=C2OC)C3=CN=C(C(C(F)(F)F)=C3)N4CCC(C)(CC4)N.Cl
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
TLR7 antagonist-1 関連分類
HY-181796 関連分類
Powered by Bioz